Postnatal genetic testing on cord blood for prenatally identified high‐probability cases

Abstract

AbstractObjectiveTo evaluate the utility of postnatal genetic testing on umbilical cord blood (CB) for prenatally identified high‐probability fetuses.MethodCB for genetic testing was offered to individuals who met one of the following criteria: (i) fetal anomaly, (ii) positive non‐invasive prenatal screening by cfDNA or biochemical analysis, or (iii) family history. Individuals with diagnostic testing, but not microarray, were also included when recommended by society guidelines. CB was collected at Brigham and Women's and Emerson Hospitals between 2016 and 2021.Results448 individuals consented for cord blood testing (370 (82.6%) for fetal anomalies, 51 (11.4%) for high‐probability cfDNA, and 27 (6.0%) for family history) and a total of 393 (87.7%) samples were analyzed. Genetic testing yielded a diagnosis in 92 (23.4%) neonates by karyotype (n = 37), chromosomal microarray (CMA) (n = 32), and other molecular analysis (n = 23). Testing averaged 10.3 days (range 1–118 days). 68 (73.9%) diagnoses potentially impacted neonatal management. MCC could not be definitively excluded in only 1.4% (6/418) of samples.ConclusionPrenatal identification of high‐probability fetuses and genetic testing on CB facilitates timely genetic diagnoses and neonatal management. Testing provides reassurance and reduces a postnatal diagnostic odyssey for high‐probability neonates.